Diabetes Metab J.  2015 Apr;39(2):171-172. 10.4093/dmj.2015.39.2.171.

Letter: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)

• Seok H

• KMID: 1805901
• DOI: http://doi.org/10.4093/dmj.2015.39.2.171

Abstract

No abstract available.

MeSH Terms

Humans
Metformin*
Metformin

Reference

1. Kawalec P, Mikrut A, Lopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014; 30:269–283.

2. Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014; 5:138–146.

3. Sicras-Mainar A, Navarro-Artieda R. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients. Diabetes Metab J. 2015; 39:74–81.

4. Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J. 2011; 35:437–443.

5. Angeli FS, Shannon RP. Beyond glycemic control: cardiovascular effects of incretin-based therapies. Front Horm Res. 2014; 43:144–157.